Immunogen Inc (IMGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2022 | 03-2022 | 12-2021 | 09-2021 | 06-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -86,166 | -24,145 | -139,303 | -102,131 | -64,792 |
| Depreciation Amortization | 931 | 473 | 2,017 | 1,555 | 1,093 |
| Accounts receivable | 4,029 | 1,979 | -6,766 | -4,881 | -4,188 |
| Accounts payable and accrued liabilities | -1,249 | -2,308 | 9,148 | 1,354 | 2,482 |
| Other Working Capital | -26,275 | -21,022 | -23,553 | -9,925 | -8,846 |
| Other Operating Activity | 3,337 | 3,621 | -10,959 | -9,514 | -14,249 |
| Operating Cash Flow | $-105,393 | $-41,402 | $-169,416 | $-123,542 | $-88,500 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -514 | -307 | -1,434 | -1,065 | -940 |
| Investing Cash Flow | $-514 | $-307 | $-1,434 | $-1,065 | $-940 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | N/A | N/A | -1,100 | -1,100 | N/A |
| Common Stock Issued | 1,031 | 620 | 356,844 | 77,612 | 35,122 |
| Financing Cash Flow | $1,031 | $620 | $355,744 | $76,512 | $35,122 |
| Beginning Cash Position | 478,750 | 478,750 | 293,856 | 293,856 | 293,856 |
| End Cash Position | 373,874 | 437,661 | 478,750 | 245,761 | 239,538 |
| Net Cash Flow | $-104,876 | $-41,089 | $184,894 | $-48,095 | $-54,318 |
| Free Cash Flow | |||||
| Operating Cash Flow | -105,393 | -41,402 | -169,416 | -123,542 | -88,500 |
| Capital Expenditure | -514 | -307 | -1,434 | -1,065 | -940 |
| Free Cash Flow | -105,907 | -41,709 | -170,850 | -124,607 | -89,440 |